| Fox, Erin |
NCT06329791: A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED) |
|
|
| Active, not recruiting | 3 | 500 | US | AZR-MD-001, AZR-MD-001 ophthalmic ointment 0.5%, Vehicle, AZR-MD-001 Vehicle | Azura Ophthalmics, ORA, Inc. | Dry Eye Disease | 12/24 | 11/25 | | |
ReNEW, NCT06373731: Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) |
|
|
| Recruiting | 3 | 360 | Europe, US, RoW | Elamipretide, Elamipretide HCL, Placebo | Stealth BioTherapeutics Inc. | Age Related Macular Degeneration (ARMD) | 08/26 | 08/27 | | |
NCT06470373: A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration |
|
|
| Not yet recruiting | 3 | 434 | US | RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection | Rophibio, Inc. | Neovascular Age-related Macular Degeneration (nAMD) | 09/26 | 09/26 | | |
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) |
|
|
| Active, not recruiting | 2 | 300 | US | AVD-104, Avacincaptad | Aviceda Therapeutics, Inc. | Geographic Atrophy of the Macula, Macular Degeneration | 09/25 | 09/26 | | |
NCT06654193: Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury |
|
|
| Not yet recruiting | 1/2 | 70 | US | Allogeneic HB-adMSCs, Normal Saline | Hope Biosciences, The University of Texas Health Science Center, Houston, University of California, San Francisco, University of Alabama at Birmingham | Acute Kidney Injury | 01/28 | 01/28 | | |
| Recruiting | 1/2 | 63 | US | OCU410 | Ocugen | Geographic Atrophy | 09/25 | 09/25 | | |
| Recruiting | 1/2 | 42 | US | OCU410ST | Ocugen | Stargardt Disease | 10/25 | 10/25 | | |
NCT05820100: Observational Study to Assess the Reliability and Validity of the MLYMT and MLSDT |
|
|
| Completed | N/A | 35 | US | Observational | Nanoscope Therapeutics Inc. | Retinitis Pigmentosa, Retinal Dystrophy | 10/23 | 10/23 | | |
NCT06451133: Hemodynamic Management Following Acute Traumatic Spinal Cord Injury |
|
|
| Recruiting | N/A | 228 | US | Mean arterial blood pressure (MAP) goal of ≥65 mmHg, Mean arterial blood pressure (MAP) goal of 85-90 mmHg, Spinal cord perfusion pressure (SCPP) goal of ≥65 mmHg | The University of Texas Health Science Center, Houston, Trauma Research and Combat Casualty Care Collaborative (TRC4) | Spinal Cord Injuries | 09/25 | 07/26 | | |
| Not yet recruiting | N/A | 270 | US | Video conversation aid, Usual Care | The University of Texas Health Science Center, Houston | Geriatric Traumatic Injury | 06/26 | 06/26 | | |
